Table I.
Comparison of clinical characteristics between adult individuals with and without CMV disease in a matched cohort
| Characteristics | CMV disease | P-value | |
|---|---|---|---|
| Yes (n = 667) | No (n = 6,670) | ||
| Sex, male | 368 (55.17) | 3,680 (55.17) | > 0.999* |
| Age [years]: | 50.58 ±15.34 | 50.58 ±15.33 | > 0.999† |
| 20–39 | 165 (24.74) | 1,650 (24.74) | |
| 40–64 | 381 (57.12) | 3,810 (57.12) | |
| ≥ 65 | 121 (18.14) | 1,210 (18.14) | |
| Low income status | 179 (26.84) | 1,553 (23.28) | 0.039* |
| Type 2 NIDDM | 146 (21.89) | 1,460 (21.89) | > 0.999* |
| Hypertension | 260 (38.98) | 2,600 (38.98) | > 0.999* |
| Dyslipidemia | 164 (24.59) | 1,640 (24.59) | > 0.999* |
| SOT | 136 (20.39) | 3 (0.04) | < 0.001* |
| HSCT | 17 (2.55) | 0 (0.00) | < 0.001* |
| CHA2DS2-VASc Score | 1.80 ±1.46 | 1.51 ±1.39 | < 0.001† |
| Acute or subsequent MI | 10 (1.50) | 49 (0.73) | 0.035* |
| Congestive heart failure | 17 (2.55) | 52 (0.78) | < 0.001* |
| Atrial fibrillation | 9 (1.35) | 58 (0.87) | 0.214* |
| Death | 66 (9.9) | 165 (2.47) | < 0.001* |
| Follow-up duration‡ [years]: | |||
| Myocardial infarction | 3.07 ±1.60 | 3.25 ±1.52 | 0.005† |
| Congestive heart failure | 3.06 ±1.62 | 3.25 ±1.52 | 0.002† |
| Atrial fibrillation | 3.07 ±1.61 | 3.24 ±1.52 | 0.007† |
| Death | 3.09 ±1.60 | 3.26 ±1.52 | 0.005† |
Data are expressed as number (percent) or mean ± SD.
*
McNemar test;
†
Paired t-test;
‡
Between cohort entry point and development of each event in patients with new-onset MI, CHF, AF, or death, or between cohort entry point and cohort end date in patients without development of each event. CMV – cytomegalovirus, HSCT – hematopoietic stem cell transplantation, NIDDM – non-insulin dependent diabetes mellitus, MI – myocardial infarction, SOT – solid organ transplantation.